Home | Welcome to Contract Pharma   
Last Updated Sunday, October 26 2014
Print

Financial Report: Biogen Idec



By Kristin Brooks



Published January 29, 2014
Biogen Idec

4Q Revenues: $2.0 billion (+39%)

4Q Earnings: $457.3 million (+57%)

FY Revenues: $6.9 billion (+26%)

FY Earnings: $1.9 billion (+35%)

Comments: Growth in the quarter and FY were driven by sales of new multiple sclerosis drug, Tecfidera, with sales of $398 million in the quarter and $876 million for the year, and TYSABRI revenues, up 45% to $427 million in the quarter, and up 34% for the year to $1.5 billion, as a result of recording 100% of revenues after gaining full rights. AVONEX revenues were flat in the quarter at $751 million and up 3% for the year to $3.0 billion. Royalty revenues were $61 million in the quarter, up 9%, and $186 million for the year, up 10%.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On